What did the 2011 omega-3 trials show regarding ARDS?

What did the 2011 omega-3 trials show regarding ARDS?

• A. Showed improved biomarkers and outcomes
• B. Showed no improvement in biomarkers or clinical outcomes
• C. Demonstrated harm
• D. Not conducted

Answer: (B)

Omega-3 fatty acids were studied in ARDS because they were expected to modulate the inflammatory response and potentially improve lung injury. In 2011, randomized trials looked at an enteral formula enriched with omega-3s (EPA/DHA) plus gamma-linolenic acid and antioxidants. The findings showed no meaningful benefit on biomarkers of inflammation and no improvement in key clinical outcomes such as ventilator-free days, length of stay, or mortality. In other words, despite the theoretical rationale, the trials did not demonstrate a clinical or biological advantage. As a result, the evidence did not support routine use of omega-3–enriched nutrition for ARDS at that time.

Omega-3 fatty acids were studied in ARDS because they were expected to modulate the inflammatory response and potentially improve lung injury. In 2011, randomized trials looked at an enteral formula enriched with omega-3s (EPA/DHA) plus gamma-linolenic acid and antioxidants. The findings showed no meaningful benefit on biomarkers of inflammation and no improvement in key clinical outcomes such as ventilator-free days, length of stay, or mortality. In other words, despite the theoretical rationale, the trials did not demonstrate a clinical or biological advantage. As a result, the evidence did not support routine use of omega-3–enriched nutrition for ARDS at that time.